SCHEMBL2122989

SCHEMBL2122989

COC(=O)c1ccc(Nc2c(-c3cccc(C)n3)nc3c(C#N)c[nH]n23)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM5A P29375 7/20 0.48
▸ KMT2A Q03164 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.39
▸ MAPT P10636 5/20 0.39
▸ TP53 P04637 2/20 0.39
▸ LRRK2 Q5S007 1/20 0.39
▸ USP2 O75604 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ TGFBR1 P36897 2/20 0.38
▸ POLB P06746 1/20 0.37
▸ KDM6B O15054 1/20 0.37
▸ KDM5C P41229 1/20 0.37
▸ KDM5D Q9BY66 1/20 0.37
▸ KDM4C Q9H3R0 1/20 0.37
▸ KDM5B Q9UGL1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2124968 0.85 KDM5A (0.64) KDM5AMAPTTP53KDM6BKDM5C
SCHEMBL2124147 0.81 MAPT (0.52) KDM5AMAPTTP53TSHRSMN1; SMN2
SCHEMBL2127585 0.81 KDM5A (0.52) KDM5AMAPTTP53POLBKDM6B
SCHEMBL2125082 0.81 MAPT (0.43) KDM5AMAPTTP53SMN1; SMN2TGFBR1
SCHEMBL2124057 0.80 MAPT (0.54) KDM5AMAPTTP53MAPK1SMN1; SMN2
SCHEMBL2124708 0.79 MAPT (0.42) KDM5AMAPTTP53TGFBR1KDM6B
SCHEMBL2123116 0.79 KDM5A (0.47) KDM5AMAPTTP53POLB
SCHEMBL2123358 0.78 KDM5A (0.50) KDM5AKMT2AMAPTTP53LRRK2
SCHEMBL2123653 0.78 MAPT (0.46) KDM5AKDM4EMAPTTP53KDM6B
SCHEMBL2876505 0.77 MAPT (0.43) KDM5AKDM4EMAPTTP53LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443123-B1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS INC (US) 2017-04-05 — — EP disclosed
US-8377945-B2 Small molecule inhibitors of spleen tyrosine kinase (SYK) RIGEL PHARMACEUTICALS INC. (US) 2013-02-19 — — US disclosed
EP-2443123-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) Rigel Pharmaceuticals, Inc. (US) 2012-04-25 — — EP disclosed
WO-2010147898-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS, INC. (US) 2010-12-23 — — WO disclosed
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) MIDCAP FINANCIAL TRUST 2010-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) SYK, BTK, LCK KDM5A 1592/4885KMT2A 1554/4885KDM4E 1205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback